Literature DB >> 22674057

Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.

Miriam Alb1, Christopher Sie, Christian Adam, Suzie Chen, Jürgen C Becker, David Schrama.   

Abstract

Grm1-transgenic mice spontaneously develop cutaneous melanoma. This model allowed us to scrutinize the generic immune responses over the course of melanoma development. To this end, lymphocytes obtained from spleens, unrelated lymph nodes and tumor-draining lymph nodes of mice with no evidence of disease, and low or high tumor burden were analyzed ex vivo and in vitro. Thereby, we could demonstrate an increase in the number of activated CD4(+) and CD8(+) lymphocytes in the respective organs with increasing tumor burden. However, mainly CD4(+) T cells, which could constitute both T helper as well as immunosuppressive regulatory T cells, but not CD8(+) T cells, expressed activation markers upon in vitro stimulation when obtained from tumor-bearing mice. Interestingly, these cells from tumor-burdened animals were also functionally hampered in their proliferative response even when subjected to strong in vitro stimulation. Further analyses revealed that the increased frequency of regulatory T cells in tumor-bearing mice is an early event present in all lymphoid organs. Additionally, expression of the immunosuppressive cytokines TGF-β1 and IL-10 became more evident with increased tumor burden. Notably, TGF-β1 is strongly expressed in both the tumor and the tumor-draining lymph node, whereas IL-10 expression is more pronounced in the lymph node, suggesting a more complex regulation of IL-10. Thus, similar to the situation in melanoma patients, both cytokines as well as cellular immune escape mechanisms seem to contribute to the observed immunosuppressed state of tumor-bearing grm1-transgenic mice, suggesting that this model is suitable for preclinical testing of immunomodulatory therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674057      PMCID: PMC3506202          DOI: 10.1007/s00262-012-1290-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  45 in total

1.  Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion.

Authors:  Andrew J Russ; Kyle Xu; Lucy Wentworth; Sheeba Alam; Justin V Meyers; Michael D Macklin; Alexander L Rakhmilevich; Victoria Rajamanickam; M Suresh; Clifford S Cho
Journal:  Cell Immunol       Date:  2011-06-17       Impact factor: 4.868

2.  Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Immunol Immunother       Date:  2011-11-27       Impact factor: 6.968

3.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Authors:  M H Andersen; L O Pedersen; B Capeller; E B Bröcker; J C Becker; P thor Straten
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 4.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

5.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 6.  Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.

Authors:  Teresa Ramirez-Montagut; Mary Jo Turk; Jedd D Wolchok; José A Guevara-Patino; Alan N Houghton
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

7.  Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.

Authors:  Keishi Fujiwara; Toshihiro Higashi; Kazuhiro Nouso; Harushige Nakatsukasa; Yoshiyuki Kobayashi; Masayuki Uemura; Shin-Ichiro Nakamura; Shuichiro Sato; Tadashi Hanafusa; Yasuhiro Yumoto; Ichiro Naito; Yasushi Shiratori
Journal:  J Gastroenterol Hepatol       Date:  2004-10       Impact factor: 4.029

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.

Authors:  Matthew P Rausch; K Taraszka Hastings
Journal:  J Invest Dermatol       Date:  2011-08-11       Impact factor: 8.551

View more
  5 in total

Review 1.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

Review 2.  The lymph node microenvironment and its role in the progression of metastatic cancer.

Authors:  Ethel R Pereira; Dennis Jones; Keehoon Jung; Timothy P Padera
Journal:  Semin Cell Dev Biol       Date:  2015-01-22       Impact factor: 7.727

3.  Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.

Authors:  Xiaoying Wang; Fengshu Zhao; Xiangfeng He; Jing Wang; Ying Zhang; Hongyi Zhang; Yaoyao Ni; Jianan Sun; Xiaobing Wang; Jun Dou
Journal:  Oncotarget       Date:  2015-05-20

Review 4.  Overcoming Immune Evasion in Melanoma.

Authors:  Kevinn Eddy; Suzie Chen
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

5.  Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy.

Authors:  Ronak Savla; Olga B Garbuzenko; Suzie Chen; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Pharm Res       Date:  2014-06-13       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.